Products

At HemoSphere Bio, we develop innovative therapies to treat coagulation disorders, improve patient outcomes and advance care for those with bleeding and thrombotic conditions.

HemoFlow (Approved product)

Indication: Anticoagulation / Blood clot prevention

Description: Our blood thinner is a proven therapy that helps reduce the risk of dangerous blood clots in patients at risk of thrombosis. With a strong safety profile and easy-to-use administration, it supports patients in maintaining an active, healthy lifestyle.

Key Benefits:

  • Effectively prevents blood clot formation

  • Well-tolerated with minimal side effects

  • Trusted by physicians and patients across Europe

Octomab (in development)

Indication: Hemophilia A

Description: Octomab is a humanized bispecific monoclonal antibody designed to prevent bleeding episodes in patients with Hemophilia A. Unlike traditional therapies, Octomab does not replace Factor VIII directly. Instead, it functionally mimics the role of Factor VIII in the coagulation cascade, helping restore proper clotting.

As a prophylactic therapy, Octomab is administered regularly to reduce the frequency and severity of bleeding events, improving patients’ quality of life and enabling more active, everyday living. Its targeted, non-factor mechanism represents a novel approach to Hemophilia A treatment, offering an alternative for patients who can't use conventional Factor VIII therapies.

Development Status: Octomab is currently in clinical development, with EMA approval planned for 2031.

Key Benefits:

  • Novel non-factor therapy with a precise, targeted mechanism

  • Effective for patients without inhibitors to Factor VIII

  • Provides prophylactic protection against bleeding episodes

  • Designed for patient-friendly administration and improved quality of life